The follicle stimulating hormone market size has grown steadily in recent years. It will grow from $2.12 billion in 2025 to $2.22 billion in 2026 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to advancements in recombinant hormone production, rising infertility cases, growth of healthcare infrastructure, increased awareness of fertility treatments, adoption of urinary fsh formulations.
The follicle stimulating hormone market size is expected to see strong growth in the next few years. It will grow to $2.76 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to technological innovations in fsh delivery systems, growth of assisted reproductive technology (art) centers, expansion of telehealth for fertility care, government support for infertility treatments, increasing demand for personalized medicine in reproductive health. Major trends in the forecast period include personalized fertility treatments, increased use of recombinant hormones, integration of telemedicine in fertility care, focus on female reproductive health awareness, expansion of assisted reproductive technology (art) clinics.
The rising adoption of assisted reproductive technology is anticipated to drive the growth of the follicle-stimulating hormone market in the coming years. Assisted reproductive technology (ART) refers to a range of medical procedures and practices designed to help individuals or couples conceive when conventional methods are unsuccessful. The use of follicle-stimulating hormone in ART is a well-established therapeutic approach aimed at enhancing the likelihood of successful pregnancy outcomes for those facing reproductive challenges. For example, in March 2024, according to the U.S. Department of Health and Human Services, a US-based government agency, the use of assisted reproductive technology increases with maternal age. In 2023, approximately 9% of live births among women aged 40-45 involved ART, with the proportion rising to nearly one-third among women aged 45 and older. ART utilization also varies by region across the United States. Consequently, the increasing adoption of assisted reproductive technology is contributing to the growth of the follicle-stimulating hormone market.
Major companies operating in the follicle-stimulating hormone market are focusing on the development of innovative solutions such as multi-hormone at-home diagnostic testing systems to deliver more precise, continuous, and patient-centered insights into hormone health and reproductive function. Multi-hormone at-home diagnostic testing systems are integrated, user-friendly platforms that assess follicle-stimulating hormone alongside other key reproductive hormones using non-invasive sampling methods. These systems enable real-time monitoring, personalized health insights, and improved clinical decision-making without the need for in-clinic testing. For instance, in July 2024, Proov, a US-based women’s health company, launched the Proov Empower Perimenopause Testing System. Proov Empower provides personalized insights into how hormonal changes affect overall health and wellness. This non-invasive, multi-time-point urine test measures four essential hormones - FSH, estrogen marker E1G, progesterone marker PdG, and luteinizing hormone (LH) - that influence perimenopause symptoms. Through periodic retesting, the system enables women to track hormone fluctuations and associated symptoms, offering guidance during the transition to menopause.
In September 2024, Organon China, a China-based healthcare company, partnered with Shanghai Bao Pharmaceutical for the development of SJ02, a long-acting follicle-stimulating hormone candidate in the biologics license application process and an innovative investigational asset for assisted reproductive technology in mainland China. Through this collaboration, Organon is advancing its “In China, for China” strategy while expanding its fertility portfolio. By working with leading domestic innovators, Organon aims to accelerate progress in assisted reproductive technology and broaden access to fertility treatment options for millions of families in China. Shanghai Bao Pharmaceutical is a China-based provider specializing in follicle-stimulating hormone products.
Major companies operating in the follicle stimulating hormone market are Pfizer Inc., Sanofi S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Cipla Ltd., Ferring Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Emcure Pharmaceuticals Ltd., IBSA Group, Taj Pharmaceuticals Ltd., Trumac Healthcare, Midas Pharma GmbH, Shanghai Techwell Biopharmaceutical Co. Ltd., Livzon Pharmaceutical Group Inc., Anhui Anke Biotechnology Group Co. Ltd., LG Chem Life Sciences, Genpharm Inc., Biogenix Inc. Pvt. Ltd.
North America was the largest region in the follicle stimulating hormone market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the follicle stimulating hormone market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the follicle stimulating hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the follicle-stimulating hormone market by increasing the cost of imported active pharmaceutical ingredients and raw materials, causing disruptions in the production of recombinant and urinary FSH products. Segments such as recombinant FSH formulations and infertility treatment centers in regions like North America, Europe, and Asia-Pacific are most affected due to dependency on global supply chains. While tariffs have raised production costs, they have also encouraged local manufacturing and innovation in cost-effective FSH solutions, creating opportunities for domestic suppliers.
The follicle stimulating hormone market research report is one of a series of new reports that provides follicle stimulating hormone market statistics, including follicle stimulating hormone industry global market size, regional shares, competitors with a follicle stimulating hormone market share, detailed follicle stimulating hormone market segments, market trends and opportunities, and any further data you may need to thrive in the follicle stimulating hormone industry. This follicle stimulating hormone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Follicle-stimulating hormone is a hormone secreted by the pituitary gland that plays a key role in sexual development and reproduction. It influences the functioning of the testes and ovaries and helps regulate egg production in the ovaries as well as the menstrual cycle.
The main types of follicle-stimulating hormones include recombinant FSH and urinary FSH. Recombinant FSH is produced using recombinant DNA technology rather than being derived from natural sources such as urine. These hormones are used in applications such as infertility treatment, assisted reproductive technology (ART), and others, and are utilized by end users including infertility centers, hospitals, and other healthcare facilities.
The follicle-stimulating hormone market consists of sales of luteinizing hormone (LH), chorionic gonadotropin (CG), and thyroid-stimulating hormone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The follicle stimulating hormone market size is expected to see strong growth in the next few years. It will grow to $2.76 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to technological innovations in fsh delivery systems, growth of assisted reproductive technology (art) centers, expansion of telehealth for fertility care, government support for infertility treatments, increasing demand for personalized medicine in reproductive health. Major trends in the forecast period include personalized fertility treatments, increased use of recombinant hormones, integration of telemedicine in fertility care, focus on female reproductive health awareness, expansion of assisted reproductive technology (art) clinics.
The rising adoption of assisted reproductive technology is anticipated to drive the growth of the follicle-stimulating hormone market in the coming years. Assisted reproductive technology (ART) refers to a range of medical procedures and practices designed to help individuals or couples conceive when conventional methods are unsuccessful. The use of follicle-stimulating hormone in ART is a well-established therapeutic approach aimed at enhancing the likelihood of successful pregnancy outcomes for those facing reproductive challenges. For example, in March 2024, according to the U.S. Department of Health and Human Services, a US-based government agency, the use of assisted reproductive technology increases with maternal age. In 2023, approximately 9% of live births among women aged 40-45 involved ART, with the proportion rising to nearly one-third among women aged 45 and older. ART utilization also varies by region across the United States. Consequently, the increasing adoption of assisted reproductive technology is contributing to the growth of the follicle-stimulating hormone market.
Major companies operating in the follicle-stimulating hormone market are focusing on the development of innovative solutions such as multi-hormone at-home diagnostic testing systems to deliver more precise, continuous, and patient-centered insights into hormone health and reproductive function. Multi-hormone at-home diagnostic testing systems are integrated, user-friendly platforms that assess follicle-stimulating hormone alongside other key reproductive hormones using non-invasive sampling methods. These systems enable real-time monitoring, personalized health insights, and improved clinical decision-making without the need for in-clinic testing. For instance, in July 2024, Proov, a US-based women’s health company, launched the Proov Empower Perimenopause Testing System. Proov Empower provides personalized insights into how hormonal changes affect overall health and wellness. This non-invasive, multi-time-point urine test measures four essential hormones - FSH, estrogen marker E1G, progesterone marker PdG, and luteinizing hormone (LH) - that influence perimenopause symptoms. Through periodic retesting, the system enables women to track hormone fluctuations and associated symptoms, offering guidance during the transition to menopause.
In September 2024, Organon China, a China-based healthcare company, partnered with Shanghai Bao Pharmaceutical for the development of SJ02, a long-acting follicle-stimulating hormone candidate in the biologics license application process and an innovative investigational asset for assisted reproductive technology in mainland China. Through this collaboration, Organon is advancing its “In China, for China” strategy while expanding its fertility portfolio. By working with leading domestic innovators, Organon aims to accelerate progress in assisted reproductive technology and broaden access to fertility treatment options for millions of families in China. Shanghai Bao Pharmaceutical is a China-based provider specializing in follicle-stimulating hormone products.
Major companies operating in the follicle stimulating hormone market are Pfizer Inc., Sanofi S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Cipla Ltd., Ferring Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Emcure Pharmaceuticals Ltd., IBSA Group, Taj Pharmaceuticals Ltd., Trumac Healthcare, Midas Pharma GmbH, Shanghai Techwell Biopharmaceutical Co. Ltd., Livzon Pharmaceutical Group Inc., Anhui Anke Biotechnology Group Co. Ltd., LG Chem Life Sciences, Genpharm Inc., Biogenix Inc. Pvt. Ltd.
North America was the largest region in the follicle stimulating hormone market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the follicle stimulating hormone market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the follicle stimulating hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have impacted the follicle-stimulating hormone market by increasing the cost of imported active pharmaceutical ingredients and raw materials, causing disruptions in the production of recombinant and urinary FSH products. Segments such as recombinant FSH formulations and infertility treatment centers in regions like North America, Europe, and Asia-Pacific are most affected due to dependency on global supply chains. While tariffs have raised production costs, they have also encouraged local manufacturing and innovation in cost-effective FSH solutions, creating opportunities for domestic suppliers.
The follicle stimulating hormone market research report is one of a series of new reports that provides follicle stimulating hormone market statistics, including follicle stimulating hormone industry global market size, regional shares, competitors with a follicle stimulating hormone market share, detailed follicle stimulating hormone market segments, market trends and opportunities, and any further data you may need to thrive in the follicle stimulating hormone industry. This follicle stimulating hormone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Follicle-stimulating hormone is a hormone secreted by the pituitary gland that plays a key role in sexual development and reproduction. It influences the functioning of the testes and ovaries and helps regulate egg production in the ovaries as well as the menstrual cycle.
The main types of follicle-stimulating hormones include recombinant FSH and urinary FSH. Recombinant FSH is produced using recombinant DNA technology rather than being derived from natural sources such as urine. These hormones are used in applications such as infertility treatment, assisted reproductive technology (ART), and others, and are utilized by end users including infertility centers, hospitals, and other healthcare facilities.
The follicle-stimulating hormone market consists of sales of luteinizing hormone (LH), chorionic gonadotropin (CG), and thyroid-stimulating hormone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Follicle Stimulating Hormone Market Characteristics
3. Follicle Stimulating Hormone Market Supply Chain Analysis
4. Global Follicle Stimulating Hormone Market Trends and Strategies
5. Follicle Stimulating Hormone Market Analysis of End Use Industries
7. Global Follicle Stimulating Hormone Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Follicle Stimulating Hormone Total Addressable Market (TAM) Analysis for the Market
9. Follicle Stimulating Hormone Market Segmentation
10. Follicle Stimulating Hormone Market Regional and Country Analysis
11. Asia-Pacific Follicle Stimulating Hormone Market
12. China Follicle Stimulating Hormone Market
13. India Follicle Stimulating Hormone Market
14. Japan Follicle Stimulating Hormone Market
15. Australia Follicle Stimulating Hormone Market
16. Indonesia Follicle Stimulating Hormone Market
17. South Korea Follicle Stimulating Hormone Market
18. Taiwan Follicle Stimulating Hormone Market
19. South East Asia Follicle Stimulating Hormone Market
20. Western Europe Follicle Stimulating Hormone Market
21. UK Follicle Stimulating Hormone Market
22. Germany Follicle Stimulating Hormone Market
23. France Follicle Stimulating Hormone Market
24. Italy Follicle Stimulating Hormone Market
25. Spain Follicle Stimulating Hormone Market
26. Eastern Europe Follicle Stimulating Hormone Market
27. Russia Follicle Stimulating Hormone Market
28. North America Follicle Stimulating Hormone Market
29. USA Follicle Stimulating Hormone Market
30. Canada Follicle Stimulating Hormone Market
31. South America Follicle Stimulating Hormone Market
32. Brazil Follicle Stimulating Hormone Market
33. Middle East Follicle Stimulating Hormone Market
34. Africa Follicle Stimulating Hormone Market
36. Follicle Stimulating Hormone Market Competitive Landscape and Company Profiles
37. Follicle Stimulating Hormone Market Other Major and Innovative Companies
40. Follicle Stimulating Hormone Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Follicle Stimulating Hormone Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses follicle stimulating hormone market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for follicle stimulating hormone? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The follicle stimulating hormone market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Recombinant FSH; Urinary FSH2) By Application: Infertility Treatment; Assisted Reproductive Technology (ART); Other Applications
3) By End-Users: Infertility Center; Hospitals; Other End-Users
Subsegments:
1) By Recombinant FSH: Pure Recombinant FSH; Mixed Recombinant FSH Formulations2) By Urinary FSH: Purified Urinary FSH; Urinary FSH Combined With Other Hormones
Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Merck KGaA; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Intas Pharmaceuticals Ltd.; Cipla Ltd.; Ferring Pharmaceuticals Inc.; Lupin Limited; Zydus Lifesciences Limited; Emcure Pharmaceuticals Ltd.; IBSA Group; Taj Pharmaceuticals Ltd.; Trumac Healthcare; Midas Pharma GmbH; Shanghai Techwell Biopharmaceutical Co. Ltd.; Livzon Pharmaceutical Group Inc.; Anhui Anke Biotechnology Group Co. Ltd.; LG Chem Life Sciences; Genpharm Inc.; Biogenix Inc. Pvt. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Follicle Stimulating Hormone market report include:- Pfizer Inc.
- Sanofi S.A.
- Merck KGaA
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Cipla Ltd.
- Ferring Pharmaceuticals Inc.
- Lupin Limited
- Zydus Lifesciences Limited
- Emcure Pharmaceuticals Ltd.
- IBSA Group
- Taj Pharmaceuticals Ltd.
- Trumac Healthcare
- Midas Pharma GmbH
- Shanghai Techwell Biopharmaceutical Co. Ltd.
- Livzon Pharmaceutical Group Inc.
- Anhui Anke Biotechnology Group Co. Ltd.
- LG Chem Life Sciences
- Genpharm Inc.
- Biogenix Inc. Pvt. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.22 Billion |
| Forecasted Market Value ( USD | $ 2.76 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
